Share on LinkedInShare on LinkedIn

ARTICLE · 05 JUNE 2013

The Federal Circuit Reverses Summary Judgment That Claims Were Not Obvious

In an ANDA case involving a reissue patent, the U. S. Court of Appeals for the Federal Circuit reversed a district court's summary judgment that the asserted claims of the reissue patent were not obvious.

United StatesIntellectual Property

Bayer Healthcare Pharms., Inc. v. Watson Pharms., Inc.

In an ANDA case involving a reissue patent, the U. S. Court of Appeals for the Federal Circuit reversed a district court's summary judgment that the asserted claims of the reissue patent were not obvious, finding that prior art provided the motivation to combine the teachings of the prior art to derive the claimed subject matter with a reasonable expectation of success. Bayer Healthcare Pharms., Inc. v. Watson Pharms., Inc., Case Nos. 12-1397, -1398, -1400 (Fed. Cir., Apr. 16, 2013) (Lourie, J.).

The asserted claims of the reissue patent are directed to a combination oral contraceptive (COC) with active pills containing a low dose (20 mcg) of ethinylestradiol and 2.5-3.0 mg of drospirenone that are administered in a 23- or 24-day dosage cycle followed by five or four pill-free or placebo pill days, also referred to as 23/5 and 24/4 regimens, respectively. Bayer's YAZ product embodies the claims of the reissue

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from